Compare YQ & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YQ | CNSY |
|---|---|---|
| Founded | 2012 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 20.6M |
| IPO Year | 2020 | 2016 |
| Metric | YQ | CNSY |
|---|---|---|
| Price | $3.39 | $2.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 70.8K | 62.1K |
| Earning Date | 06-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.68 | $2.31 |
| 52 Week High | $6.45 | $4.03 |
| Indicator | YQ | CNSY |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 18.89 |
| Support Level | $3.28 | N/A |
| Resistance Level | $3.68 | $3.05 |
| Average True Range (ATR) | 0.44 | 0.21 |
| MACD | 0.12 | -0.06 |
| Stochastic Oscillator | 53.56 | 2.52 |
17 Education & Technology Group Inc is engaged in providing education and education technology services in the People's Republic of China (PRC) with a focus on the Teaching and Learning SaaS offerings. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.